GlobeNewswire

Demand for Cosmetic Surgery Procedures Around the World Continues to Skyrocket - USA, Brazil, Japan, Italy and Mexico Ranked in the Top Five Countries

Dela

NEW YORK, June 27, 2017 (GLOBE NEWSWIRE) -- The International Society of Aesthetic Plastic Surgery (ISAPS) today released the results of their annual Global Aesthetic Survey for procedures completed in 2016, which showed an overall increase of 9% in surgical and non-surgical cosmetic procedures within the past twelve months.

Ranking of the World's Top Ten Countries for Cosmetic Procedures
The top five countries - USA, Brazil, Japan, Italy and Mexico - account for 41.4% of the world's cosmetic procedures, followed by Russia, India, Turkey, Germany and France.

Ranking   Country: Total 
number of 
procedures  
% of World-Wide 
Total
1 USA  4,217,862  17.9 %
2 Brazil  2,524,115  10.7 %
3 Japan  1,137,976  4.8 %
4 Italy  957,814  4.1 %
5 Mexico  923,243  3.9 %
6 Russia  896,629  3.8 %
7 India  878,180  3.7 %
8 Turkey  789,564  3.3 %
9 Germany  730,437  3.1 %
10 France  517,731  2.2 %
11 Colombia  505,161  2.1 %
12 Spain  473,074  2.0 %
13 Chinese Taipei    387,815  1.6 %
14 Egypt  376,348  1.6 %
15 Greece  287,918  1.2 %
16 Argentina  272,420  1.2 %
17 Venezuela  244,552  1.0 %
18 Australia  225,002  1.0 %
19 Belgium  195,665  0.8 %
20 Iran  151,439  0.6 %
21 Thailand  112,821  0.5 %
22 Lebanon  79,769  0.3 %
23 Romania  76,911  0.3 %
24 South Africa  45,413  0.2 %
       

The Fastest Growing Cosmetic Procedures
In 2016, Labiaplasty showed the largest increase in number of procedures from 2015, with a 45% rise, followed by the Lower Body lift which increased by 29%, the Upper Body Lift and Breast Augmentation using Fat Transfer both demonstrating equal growth at 22%, and the Buttock Lift increasing by 20%.

The Most Popular Cosmetic Surgical Procedures
Breast Augmentation continued to be the world's most popular cosmetic procedure, accounting for 15.8% of all surgical procedures, followed by Liposuction (14%), Eyelid Surgery (12.9%), Rhinoplasty (7.6%) and Abdominoplasty (7.4%). The least popular cosmetic surgery in 2016 was penile enlargement, which also saw the largest decrease in number of procedures (-28%).

The most popular non-surgical procedures continue to be injectables with Botulinum Toxin ranking at number one at 4,627,752 procedures (a 7% increase over the past 12 months).

The Gender Difference
Women continue to drive the demand for cosmetic procedures, accounting for 86.2%, or 20,362,655 cosmetic procedures worldwide. The five most popular procedures requested by women are Breast Augmentation (Silicone Implant), Liposuction, Eyelid Surgery, Abdominoplasty and Breast Lift.

In 2016, men accounted for 13.8% of cosmetic patients with 3,264,254 procedures performed worldwide. Their top five cosmetic procedures requested by men are Eyelid Surgery, Gynecomastia, Rhinoplasty, Liposuction and Hair Transplant.

President of ISAPS, Dr. Renato Saltz, comments, "These results confirm something that most board-certified plastic surgeons already knew - that the demand for cosmetic procedures is stronger than ever. Around the world, we are seeing record numbers of patients looking to take advantage of the latest innovations in cosmetic surgery to look and feel better about themselves."

Survey Methodology
The data on aesthetic/cosmetic surgical and non-surgical procedures performed in 2016 was tabulated with a questionnaire sent to approximately 35,000 plastic surgeons in ISAPS' proprietary database. ISAPS is the only organization that collects this type of cosmetic data annually on a global scale. The results were compiled, tabulated and analyzed by Industry Insights, an independent research firm based in Columbus, Ohio. For a copy of full results, please visit www.ISAPS.org.

About ISAPS
The International Society of Aesthetic Plastic Surgery is the premier global organization for board-certified plastic surgeons. Regarded as the leading global authority on aesthetics and cosmetic surgery, ISAPS has over 3,200 members in 104 countries. Through its rigorous membership requirements, ISAPS plastic surgeons are considered to be among the most qualified in their respective countries, making it easy for patients who are considering cosmetic surgery to start their journey by meeting with an ISAPS plastic surgeon. A full list of ISAPS plastic surgeons can be found at www.ISAPS.org

Media Contact: 
Julie Guest, ISAPS Chief Marketing Officer 
marketing@ISAPS.org 
1-844-867-3621



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ISAPS via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum